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Summary
 
Background
 
Discontinuation of metformin therapy, if started
beyond menarche in adolescents or young women with hyperinsuli-
naemia following low birthweight, is rapidly followed by rebound
deteriorations in body fat, insulin resistance and blood lipid profile.
 
Objective
 
We hypothesized that early commencement of met-
formin and its continuation throughout puberty might have more
persisting benefits.
 
Patients and measurements
 
We followed up on a previously
reported randomized study cohort at 12 months and 18 months after
treatment discontinuation, including body composition by absorp-
tiometry, fasting insulin, glucose and blood lipids. In that open-labelled,
prospective study, 22 low birthweight girls with early normal puberty
(Stage 2 breast development at age 8–9 years) were randomized to
remain untreated (
 
N
 
 = 12] or to receive metformin (850 mg/day;
 
N
 
 = 10) for 36 months (between time –36 months to 0 month).
 
Results
 
The significant improvements previously reported at the
end of the 36-month active treatment period in per cent body fat,
abdominal fat mass, fasting insulin sensitivity, high density lipo-
protein (HDL) cholesterol and triglyceride levels all persisted at
follow-up 12 months after treatment discontinuation. Further
anthropometry at 18 months off therapy confirmed the persistence
of benefits in height, body mass index (BMI) and waist circumference
in the previously metformin-exposed girls.
 
Conclusion
 
In low birth weight girls with early normal onset of
puberty, metformin treatment for 3 years across puberty resulted in
auxological, endocrine and metabolic benefits that persisted for at
least 1 year after metformin withdrawal. Further follow-up and
longer-term studies are needed to explore the possibility that insulin
sensitization therapy during puberty might reprogramme predis-
position to metabolic disease.
(Received 13 April 2007; returned for revision 11 May 2007; finally 
 
revised 17 May 2007; accepted 17 May 2007)
 
Introduction
 
We recently reported that long-term insulin sensitization therapy
with metformin during puberty in girls has cumulative auxological,
body composition and endocrine-metabolic benefits.
 
1
 
In that open-label randomized study, 22 girls aged 9 years with
history of low birthweight and early normal onset of puberty
received either metformin 850 mg (Dianben®, Merck, Farma y
Química, Barcelona, Spain) once daily or remained untreated for
36 months. Metformin was associated with a leaner body composi-
tion and more favourable lipid profile.
 
1
 
 Strikingly, metformin
prolonged the duration of puberty and also pubertal growth, and
consequently adult height was increased by 4 cm
 
1
 
 Those results
suggested that hyperinsulinaemia could underpin the rapid transit
through puberty and loss of adult stature seen in low birthweight
girls with early normal puberty.
 
2
 
We now report on the follow-up of that randomized study cohort
 
1
 
 at
12 month and 18 month after discontinuation of the trial medication.
 
Research design and methods
 
We report on the follow-up post-treatment discontinuation of a
previously reported open-label study of girls from Barcelona, Spain,
who were randomized to remain untreated (
 
N
 
 = 12) or to receive
metformin (850 mg once daily; 
 
N
 
 = 10) for 36 months.
 
1
 
 There were
no significant pretreatment differences between Met(+) and
Met(–) girls in any variable.
 
1
 
 Auxology, body composition by
absorptiometry and fasting endocrine-metabolic markers were
assessed at 12 months, and a further auxology-only assessment was
performed at 18 months after treatment discontinuation, using the
same protocols as previously described.
 
1
 
The original inclusion criteria included: (1) birthweight below
–1·5 standard deviation score (SDS); (2) early normal onset of breast
development between age 8–9 years; (3) central puberty, by GnRH
agonist test and pelvic ultrasound examination; and (4) height = 1
SD above mid-parental height SD. Exclusion criteria included familial
 
Correspondence: Lourdes Ibáñez, Endocrinology Unit, Hospital Sant Joan 
de Déu, University of Barcelona, Passeig de Sant Joan de Déu 2, 08950 
Esplugues, Barcelona, Spain. Tel: +34 93 2804000 ext. 2261; 
Fax: +34 93 2033959; E-mail: libanez@hsjdbcn.org
There is no conflict of interests.
Re-use of this article is permitted in accordance with the Creative Commons 
Deed, Attribution 2·5, which does not permit commercial exploitation.
 Persisting benefits of pubertal metformin
 
469
 
© 2007 The Authors
Journal compilation © 2007 Blackwell Publishing Ltd, 
 
Clinical Endocrinology
 
, 
 
67
 
, 468–471
 
or personal history of diabetes; evidence for precocious pubarche,
thyroid dysfunction or glucose intolerance; and taking any medication
known to affect gonadal function or carbohydrate metabolism.
 
1
 
 All girls
remained off metformin during the 18-month follow-up period.
The study was registered as ISRCTN06805028 and was approved by
the Institutional Review Board of St Joan University Hospital. Informed
consent was obtained from the parents and assent from the minors.
Changes in all parameters from baseline were compared between
the two groups by Mann–Whitney 
 
U
 
-tests.
 
Results
 
All the previously reported improvements in endocrine-metabolic,
body composition and anthopometric variables apparent at the end
of the 36-month active treatment period
 
1
 
 remained significantly
different between the two groups at the 48 months assessment (i.e.
12 months after treatment discontinuation) (Fig. 1, Table 1).
Not surprisingly, following discontinuation of insulin sensitiza-
tion therapy there was an initial partial convergence between the two
Fig. 1 Changes in hormone-metabolic, body composition and anthropometric variables from pretreatment baseline (0 month), during the 36-month 
metformin 850 mg daily treatment study (shaded area; previously reported in1), and at 12 months and 18 months after treatment discontinuation (times: 
48 months and 54 months). Means and 95% CI are shown. *P < 0·05 and **P < 0·005 by Mann–Whitney U-tests for the Untreated vs. Metformin groups at 
each time-point.
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Table 1.
 
Clinical, endocrine-metabolic and body composition indices in girls with low birthweight and early normal pubertal onset, who were randomized to remain untreated (
 
N
 
 = 12) or to receive metformin 
850 mg daily (
 
N
 
 = 10) for 36 months, and then followed up for 18 months after discontinuation of treatment
0 month (treatment start) 36 months (treatment stop)
48 months (12 month post-
treatment) †Comparison of 
changes from 
36–48 months
54 months (18 months 
post-treatment)
Untreated Metformin Untreated Metformin Untreated Metformin Untreated Metformin
Chronological age (years) 9·1 
 
±
 
 0·1 9·0 
 
±
 
 0·1 12·2 
 
±
 
 0·1 12·1 
 
±
 
 0·1 13·2 
 
±   0·1 13·1  ±   0·1 NS 13·7 
 
±   0·1 13·6 
 
±
 
 0·1
Mid-parental height (cm) 157·6  ±   1·3 159·6 
 
±
 
 1·3 – – – – – –
 
–
 Height above MPH (cm) –19·3  ±   1·2 –19·1 
 
±
 
 1·6 –3·3 
 
±
 
 0·9 0·4 
 
±
 
 0·7*** –3·0 
 
±
 
 1·0 0·9 
 
±
 
 0·7*** 0·02
 
–
 
3·0 
 
±
 
 1·0 1·1 
 
±
 
 0·7***
BMI (kg/m
 
2
 
) 20·2 
 
±
 
 0·8 21·0 
 
±
 
 0·8 22·7 
 
±
 
 0·5 21·6 
 
±
 
 0·6*** 23·2 
 
±
 
 0·6 22·3 
 
±
 
 0·5** NS 23·6 
 
±
 
 0·5 22·7 
 
±
 
 0·5**
Waist circ. (cm) 64·3 
 
±
 
 1·8 68·3 
 
±
 
 2·3 75·1 
 
±
 
 1·2 71·2 
 
±
 
 1·5*** 76·4 
 
±
 
 1·2 73·4 
 
±
 
 1·5*** 0·02 77·5 
 
±
 
 1·5 73·8 
 
±
 
 1·4***
Fasting glucose (mg/dl) 84·7 
 
±
 
 1·8 83·6 
 
±
 
 1·8 93·7 
 
±
 
 2·4 89·3 
 
±
 
 1·0 91·2 
 
±
 
 2·2 91·3 
 
±
 
 1·3 0·004
Fasting insulin (mU/l) 11·8 
 
±
 
 1·6 14·2 
 
±
 
 2·2 15·0 
 
±
 
 1·7 10·1 
 
±
 
 1·0* 16·2 
 
±
 
 1·5 14·4 
 
±
 
 1·4 0·01
 
–
 
–
Testosterone (ng/dl) 38·9 
 
±
 
 4·0 30·2 
 
±
 
 2·6 44·4 
 
±
 
 4·7 38·1 
 
±
 
 3·5 51·0 
 
±
 
 3·1 45·2 
 
±
 
 3·2 NS
 
–
 
–
SHBG (
 
µ
 
g/dl) 1·2 
 
±
 
 0·1 1·0 
 
±
 
 0·1 0·9 
 
±
 
 0·1 1·2 
 
±
 
 0·1*** 0·9 
 
±
 
 0·1 1·1 
 
±
 
 0·1** 0·0004
 
–
 
–
IGF-I (ng/ml) 298 
 
±
 
 17 292 
 
±
 
 23 268 
 
±
 
 26 197 
 
±
 
 6* 277 
 
±
 
 22 231 
 
±
 
 10 NS
 
–
 
–
HDL cholesterol (mg/l) 56 
 
±
 
 4 51 
 
±
 
 5 46 
 
±
 
 2 61 
 
±
 
 2*** 44 
 
±
 
 2 56 
 
±
 
 2*** NS
 
–
 
–
LDL cholesterol (mg/l) 102 
 
±
 
 5 93 
 
±
 
 4 110 
 
±
 
 4 90 
 
±
 
 2** 116 
 
±
 
 4 99 
 
±
 
 3** NS
 
–
 
–
Triglycerides (mg/l) 76 
 
±
 
 11 80 
 
±
 
 18 87 
 
±
 
 6 58 
 
±
 
 3*** 87 
 
±
 
 5 61 
 
±
 
 3*** NS
 
–
 
–
Percent body fat (%) 31·5 34·2 39·1 31·7*** 39·9 34·2*** 0·00001
 
–
 
–
Abdominal fat mass (kg) 3·7 
 
±
 
 0·5 4·7 
 
±
 
 0·6 6·5 
 
±
 
 0·5 4·9 
 
±
 
 0·5*** 7·0 
 
±
 
 0·5 5·8 
 
±
 
 0·6*** 0·02
 
–
 
–
Lean body mass (kg) 25·2 
 
±
 
 1·2 26·6 ± 1·0 31·8 ± 1·1 36·0 ± 0·8*** 32·3 ± 1·1 36·6 ± 0·8*** NS – –
Bone mineral density (g/cm2) 0·78 ± 0·02 0·83 ± 0·03 1·06 ± 0·03 1·12 ± 0·02 1·11 ± 0·02 1·16 ± 0·02 NS – –
Values are mean ± SEM. MPH, mid-parental height; BMI, body mass index; SHBG, sex hormone binding globulin; IGF-I, insulin-like growth factor-I; HDL, high density lipoprotein; LDL, low density lipoprotein.
*P < 0·05, **P < 0·01, ***P < 0·001 for the Untreated vs. Metformin groups at each time-point. Comparisons at 36 months, 48 months and 54 months are adjusted for baseline pretreatment (0 month) values, 
using analysis of covariance. All comparisons at baseline pretreatment P > 0·1. NS, nonsignificant.
†Changes in each variable between 36 months and 48 months (the first 12 months post-treatment) were compared between Metformin and Untreated groups by using t-tests.
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groups in levels of insulin resistance and sex hormone binding
globulin (SHBG) from 36 months to 48 months. However, the size
of benefit in HDL cholesterol and triglycerides levels remained
unchanged during this 12-month period off treatment (Fig 1 and
Table 1). Similarly, while there was some significant increase in per-
centage body fat during the 12 months following discontinuation
of metformin (from 31·7% at 36 months to 34·2% at 48 months),
the reduction compared to the untreated group remained sizable at
48 months (8·3% less gain in percentage body fat from baseline;
Fig. 1).
At 54 months (18 months after discontinuation), a further assess-
ment was made of anthropometry only. No further gains in height
were seen in either group and the significant benefit in waist circum-
ference persisted without any obvious further convergence between
the two groups (Fig. 1, Table 1).
Discussion
In low birthweight girls with early normal onset of puberty, met-
formin treatment for 36 months across puberty resulted in auxological,
body composition, endocrine and metabolic benefits that persisted
for at least 1 year after metformin discontinuation. The previously
reported active treatment phase of this study tested the hypothesis
that pubertal insulin sensitization delays menarche and prolongs
height gains in these girls.1 That study also demonstrated the role of
insulin on the pubertal changes in body composition and blood lipid
profile.1
The current observations are in contrast to previous studies in
older postmenarcheal girls aged 12–18 years and in young women
with history of low birthweight and precocious pubarche in whom
reversal of the body composition and endocrine-metabolic benefits
of metformin, with or without flutamide, were rapidly apparent
within 3–6 months off treatment.3–5 Those studies suggested that
continuous metformin therapy was necessary in such low birth-
weight girls.3–5 Our present findings therefore raise the possibility
that early introduction of insulin sensitization therapy and its
continuation throughout puberty might have long-term benefits, or
even possibly reprogramme6 the predisposition towards adverse
metabolic disease risk in these low birthweight girls.
An alternative explanation might be that previous metformin
therapy in these girls delayed not only their pubertal progression, but
also simply delayed their age-related increase in hyperinsulinaemia.
At the 48-month follow-up, metformin-exposed girls were on average
2 years beyond menarche compared to 3 years postmenarche in the
untreated girls, and it is possible that they have an overall slower tempo
of growth, maturation and also metabolic deterioration. Reassur-
ingly, between 12 months and 18 months the metformin-exposed
girls maintained their lower BMI and waist circumference compared
to previously untreated girls. However, further repeated endocrine-
metabolic assessments and other longer-term studies will be needed
to demonstrate the duration of benefit of pubertal metformin therapy.
Furthermore, the study was unblinded and included a small
number of patients. However, with the current knowledge at the time
of recruitment we considered that it would have been difficult to per-
form a blinded placebo-controlled study over such a long timescale
in children, and although dietary records were not obtained at any
time-point, there were no obvious differences in lifestyle or behaviour
observed. Further studies will also need to investigate whether our
findings in girls with history of low birthweight and early puberty
are representative of other childhood populations characterized by
insulin resistance, such as children with low birthweight, postnatal
catch-up growth, and/or obesity.7,8
In conclusion, in low birthweight girls with early normal puberty,
pubertal metformin treatment appears to have persisting endo-
crine-metabolic and body composition benefits for at least up to
12 months after discontinuation. These benefits add to the previ-
ously reported beneficial effects on later age at menarche and taller
adult height.1
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